Journal article

POSNOC-POsitive Sentinel NOde: Adjuvant therapy alone versus adjuvant therapy plus Clearance or axillary radiotherapy: A randomised controlled trial of axillary treatment in women with early-stage breast cancer who have metastases in one or two sentinel nodes

A Goyal, GB Mann, L Fallowfield, L Duley, M Reed, D Dodwell, RE Coleman, A Fakis, R Newcombe, V Jenkins, D Whitham, M Childs, D Whynes, V Keeley, I Ellis, P Fairbrother, S Sadiq, K Monson, A Montgomery, W Tan Show all

BMJ Open | BMJ PUBLISHING GROUP | Published : 2021

Abstract

Introduction ACOSOG-Z0011(Z11) trial showed that axillary node clearance (ANC) may be omitted in women with ≤2 positive nodes undergoing breast conserving surgery (BCS) and whole breast radiotherapy (RT). A confirmatory study is needed to clarify the role of axillary treatment in women with ≤2 macrometastases undergoing BCS and groups that were not included in Z11 for example, mastectomy and those with microscopic extranodal invasion. The primary objective of POsitive Sentinel NOde: adjuvant therapy alone versus adjuvant therapy plus Clearance or axillary radiotherapy (POSNOC) is to evaluate whether for women with breast cancer and 1 or 2 macrometastases, adjuvant therapy alone is non-inferi..

View full abstract

University of Melbourne Researchers

Grants

Awarded by Health Technology Assessment Programme


Funding Acknowledgements

The trial is sponsored by the University Hospitals of Derby and Burton NHS Foundation Trust(uhdb.sponsor@nhs.net).Sponsor staff -Daniel Davis, Joanne Thornhill, Anne Shaw, Amy Farmer, Teresa Grieve. This project is funded by the National Institute for Health Research Health Technology Assessment Programme (project number 12/35/17). Australian and New Zealand participation is funded by National Health and Medical Research Council (NHMRC) (project grant 1083172).